Skip to main content
. Author manuscript; available in PMC: 2010 Nov 22.
Published in final edited form as: Diabetologia. 2008 Dec 23;52(3):385–393. doi: 10.1007/s00125-008-1239-x

Fig. 2.

Fig. 2

Changes in: a serum insulin concentration (ΔSSSI; p=0.6 placebo, p<0.0001 salsalate, follow-up vs baseline by paired t test; p<0.0001 placebo vs salsalate by ANCOVA); b GIR (ΔGIR; p=0.9 placebo, p=0.004 salsalate; p=0.04 placebo vs salsalate); c EGP (ΔEGP; p=0.3 placebo, p=0.5 salsalate; p=0.9 placebo vs salsalate); and d RdRd, adjusted for steady-state glucose; p=0.7 placebo, p=0.003 salsalate; p=0.02 placebo vs salsalate) during euglycaemic hyperinsulinaemia after treatment with placebo or salsalate. Data boxes display median (solid line), mean (dotted line), quartiles (box), and 10th and 90th percentiles (error bars)

HHS Vulnerability Disclosure